<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2421">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659122</url>
  </required_header>
  <id_info>
    <org_study_id>AT-100/002</org_study_id>
    <nct_id>NCT04659122</nct_id>
  </id_info>
  <brief_title>A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection</brief_title>
  <official_title>Phase 1b Open-label, Single Arm, Cohort Dose Escalation Study Evaluating the Safety, Tolerability, and Feasibility of Intervention With AT-100 (rhSP-D) in Intubated Patients Receiving Invasive Mechanical Ventilation With Severe COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Airway Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Airway Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an investigational drug, AT-100, is safe and&#xD;
      tolerated by adults who have severe corona virus disease 2019 (COVID-19).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase 1b portion is a dose escalation study to establish the safest &amp; most tolerable AT-100 dose.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determining the highest-tolerated &amp; safety-tested AT-100 dose</measure>
    <time_frame>From time of initial AT-100 dosing until the end of the dosing period, up to 7 days</time_frame>
    <description>Dose escalation of AT-100 will occur to determine the maximum dose (in mg) that produces no significant Dose Limiting Toxicities or dose-related Adverse Events (AEs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in mechanical ventilation</measure>
    <time_frame>From mechanical ventilation initiation up to Day 28</time_frame>
    <description>Days on mechanical ventilation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>Through study completion, up to Day 90</time_frame>
    <description>Incidence of death.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>AT-100 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily AT-100 via intratracheal administration for up to 7 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-100 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily AT-100 via intratracheal administration for up to 7 doses, if the prior dose level was safe &amp; tolerated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-100 75 mg or 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily AT-100 via intratracheal administration for up to 7 doses, at the highest safe &amp; tolerated dose as determined by the prior 2 dosing levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AT-100</intervention_name>
    <description>reconstituted AT-100 for intratracheal administration</description>
    <arm_group_label>AT-100 150 mg</arm_group_label>
    <arm_group_label>AT-100 75 mg</arm_group_label>
    <arm_group_label>AT-100 75 mg or 150 mg</arm_group_label>
    <other_name>(rhSP-D)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject is an adult â‰¥18 years of age.&#xD;
&#xD;
          2. The subject has documented, laboratory-confirmed SARS-CoV-2 infection within 2 weeks&#xD;
             prior to enrollment.&#xD;
&#xD;
          3. The subject has severe SARS-CoV-2 infection requiring intubation and mechanical&#xD;
             ventilation.&#xD;
&#xD;
          4. The subject has been receiving mechanical ventilation for &lt;48 hours.&#xD;
&#xD;
          5. The subject is receiving mechanical ventilation due to respiratory disease that is&#xD;
             primarily due to SARS-CoV-2 infection.&#xD;
&#xD;
          6. The subject, or legally authorized representative if acting on the subject's behalf,&#xD;
             is able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject refuses to participate, or the subject's legally authorized representative&#xD;
             acting on the subject's behalf refuses the subject's participation.&#xD;
&#xD;
          2. The subject is pregnant or breastfeeding.&#xD;
&#xD;
          3. The subject is anticipated to be transferred to another hospital that is not a study&#xD;
             site within 36 hours of enrollment.&#xD;
&#xD;
          4. The subject has received or is receiving extracorporeal membrane oxygenation (ECMO)&#xD;
             treatment for COVID-19 treatment.&#xD;
&#xD;
          5. The subject has Human Immunodeficiency virus (HIV) under highly active antiretroviral&#xD;
             therapy (HAART).&#xD;
&#xD;
          6. The subject has cancer and is receiving chemotherapy treatment at any time during&#xD;
             trial duration, or has received chemotherapy treatment within 30 days of trial&#xD;
             enrollment.&#xD;
&#xD;
          7. The subject has a prior history of lung transplant, lobectomy, or other significant&#xD;
             lung surgeries that would indicate an already compromised lung.&#xD;
&#xD;
          8. The subject has known pulmonary air leaks, such as pneumothorax and pneumomediastinum.&#xD;
&#xD;
          9. Concurrent enrollment in an investigational product, device, or treatment trial with&#xD;
             exception of Remdesivir whether part of a clinical trial or standard-of-care&#xD;
             management.&#xD;
&#xD;
         10. The subject has a known allergy, sensitivity, or contraindication to any component of&#xD;
             the test article (AT-100).&#xD;
&#xD;
         11. The subject has any active do not resuscitate (DNR) order in place.&#xD;
&#xD;
         12. The subject's intubation, re-intubation, or remaining on intubation is not per&#xD;
             clinical standard-of-care and is solely for the purposes of administration of study&#xD;
             drug.&#xD;
&#xD;
         13. The subject has any condition or is in a situation in which, in the Investigator's&#xD;
             judgement, puts the subject at significant risk, could confound the trial results, or&#xD;
             may significantly interfere with the subject's trial participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul S. Kingma, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Airway Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc O. Salzberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Airway Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert D. Hite, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neil P. Mills, BS</last_name>
    <phone>470-486-4688</phone>
    <email>mills@airwaytherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul S. Kingma, MD, PhD</last_name>
    <phone>513-770-9630</phone>
    <email>kingma@airwaytherapeutics.com</email>
  </overall_contact_backup>
  <link>
    <url>http://www.airwaytherapeutics.com</url>
    <description>Airway Therapeutics' corporate website</description>
  </link>
  <reference>
    <citation>Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, Khan E, Mehta P, Martin-Gutierrez L, Waddington KE, Robinson GA, Ribeiro Santos L, McLoughlin E, Snell A, Adeney C, Schim van der Loeff I, Baker KF, Duncan CJA, Hanrath AT, Lendrem BC, De Soyza A, Peng J, J'Bari H, Greenwood M, Hawkins E, Peckham H, Marks M, Rampling T, Luintel A, Williams B, Brown M, Singer M, West J, Jury EC, Collin M, Tattersall RS. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020 Oct;2(10):e594-e602. doi: 10.1016/S2665-9913(20)30275-7. Epub 2020 Aug 21.</citation>
    <PMID>32864628</PMID>
  </reference>
  <reference>
    <citation>Sorensen GL. Surfactant Protein D in Respiratory and Non-Respiratory Diseases. Front Med (Lausanne). 2018 Feb 8;5:18. doi: 10.3389/fmed.2018.00018. eCollection 2018. Review.</citation>
    <PMID>29473039</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Mechanical Ventilation</keyword>
  <keyword>Respiratory Support</keyword>
  <keyword>recombinant human Surfactant Protein-D (rhSP-D)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

